StockNews.AI
ABBV
Benzinga
18 days

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

1. AbbVie reported Q2 2025 sales of $15.42 billion, beating expectations. 2. Adjusted earnings were $2.97, missing consensus of $3.23 per share. 3. Guggenheim raised revenue and EPS forecasts for 2025 due to strong product performance. 4. Analysts maintain 'Buy' ratings, increasing AbbVie's price targets. 5. Concerns about drug price pressures remain, but growth forecasts are positive.

4m saved
Insight
Article

FAQ

Why Bullish?

Despite missing earnings estimates, exceeding sales forecasts indicates strong demand, which historically supports stock prices.

How important is it?

Quarterly performance and analyst upgrades can significantly influence stock movement and investor sentiment.

Why Short Term?

Immediate impacts are linked to quarterly results and analyst updates, influencing market perception quickly.

Related Companies

Related News